CTMC Appoints Amy Hay as Chief Business Officer and Duane Avant as Chief Technical Officer

Feb 5, 2025

HOUSTON, TX, February 5, 2025 — CTMC, a joint venture between Resilience and MD Anderson Cancer Center, has appointed Amy Hay as Chief Business Officer and Duane Avant as Chief Technical Officer. The appointments are part of CTMC’s strategic growth plans to expand its support of novel cell therapy development.

Download the full article: CBOCTO-announcement_FINAL.pdf

Recent Press Releases

CTMC and Einstein Hospital Israelita in Brazil Partner to Launch the Global Cell Therapy Network Alliance

Oct 2, 2025

The CTMC Network Alliance aims to democratize and accelerate cell therapies to cancer patients globally Read the full press release: CTMC - Einstein...

CTMC and Syenex Launch Partnership to Accelerate Scalability of Cell Therapies

Jan 8, 2025

Houston, TX and Chicago, IL - January 8, 2025: CTMC, a joint venture between MD Anderson Cancer Center and Resilience, has entered a partnership...

Obsidian Therapeutics Announces Positive Interim Top-Line Clinical Data for OBX-115 Engineered TIL Cell Therapy in Advanced or Metastatic Melanoma Post-Anti-PD1 Therapy

Dec 12, 2023

CAMBRIDGE, Mass., December 12, 2023 – Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene...

Back

CTMC Appoints Amy Hay as Chief Business Officer and Duane Avant as Chief Technical Officer

Recent Press Releases

CTMC and Einstein Hospital Israelita in Brazil Partner to Launch the Global Cell Therapy Network Alliance

CTMC and Syenex Launch Partnership to Accelerate Scalability of Cell Therapies

Obsidian Therapeutics Announces Positive Interim Top-Line Clinical Data for OBX-115 Engineered TIL Cell Therapy in Advanced or Metastatic Melanoma Post-Anti-PD1 Therapy

Explore CTMC

Resources + Support

Contact Us